Omeros Corporation (NASDAQ:OMER) said on Tuesday that the U.S. FDA has accepted the resubmitted label expansion application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy, which can occur after stem cell transplants.
The biologics license application resubmission is classified as
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
